Euglena Co.,Ltd. held an earnings briefing on 19 August 2026 to explain its strategy for sustainable growth centered on its healthcare, biofuel and agri businesses. The company achieved profitability in the first half of 2026 and presented its growth strategy through 2030.
Euglena Co.,Ltd. held an earnings briefing for the second quarter of the fiscal year ending December 2026 on 19 August 2026. Representative Director and President Izumo Mitsuru (出雲 充), appearing at such an event for the first time in approximately 4.5 years, explained the company’s current position and growth strategy through 2030. The company achieved profitability in the first half of 2026 for the first time in 9 fiscal years and indicated that it had shifted toward sustainable growth while maintaining profitability.
In the healthcare business, the company has expanded its approach to new customer segments, including families raising children, in addition to its traditional senior customer base. New customer acquisition for the “Karada ni Euglena (Euglena for Your Body)” series expanded, and the number of subscription customers surpassed 13,000, approximately 9 times the year-earlier level. Growth in subscription customers and revenue was also reported for the Group as a whole.
In the biofuel business, the Malaysian commercial plant is progressing as planned toward operations beginning in the second half of 2028. The company has supplied SAF and HVO in more than 130 cases and emphasized the development of its supply structure. Although the domestic market remains at an early stage, the company expects demand to expand going forward.
The agri business’s fertilizer operations, which use Euglena-derived materials, remained solid. The agri-tech field is expected to grow as an important area closely linked to the biofuel business. The company explained that it is targeting revenue of approximately ¥100 billion and adjusted EBITDA of ¥16 billion by 2030, emphasizing initiatives to support future growth.